Annexin Pharmaceuticals AB (publ) (STO:ANNX)

Market Cap	90.71M -66.1%
Revenue (ttm)	n/a
Net Income	-39.44M
EPS	-5.60
Shares Out	7.06M
PE Ratio	n/a
Forward PE	4.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,033
Open	13.10
Previous Close	12.95
Day's Range	12.85 - 13.20
52-Week Range	11.65 - 35.80
Beta	0.29
Analysts	n/a
Price Target	75.00 (0.0%)
Earnings Date	Jul 17, 2026

About STO:ANNX

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ANNX